- Home
- RMAX vs NVCT Comparison
RMAX vs NVCT Comparison
Compare RMAX & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- NVCT
- Stock Information
- Founded
- RMAX 1973
- NVCT 2020
- Country
- RMAX United States
- NVCT United States
- Employees
- RMAX N/A
- NVCT N/A
- Industry
- RMAX Real Estate
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- RMAX Finance
- NVCT Health Care
- Exchange
- RMAX Nasdaq
- NVCT Nasdaq
- Market Cap
- RMAX 178.3M
- NVCT 167.0M
- IPO Year
- RMAX 2013
- NVCT 2022
- Fundamental
- Price
- RMAX $9.92
- NVCT $6.19
- Analyst Decision
- RMAX Hold
- NVCT Strong Buy
- Analyst Count
- RMAX 1
- NVCT 3
- Target Price
- RMAX $9.00
- NVCT $15.33
- AVG Volume (30 Days)
- RMAX 212.6K
- NVCT 60.0K
- Earning Date
- RMAX 10-30-2025
- NVCT 11-04-2025
- Dividend Yield
- RMAX N/A
- NVCT N/A
- EPS Growth
- RMAX N/A
- NVCT N/A
- EPS
- RMAX 0.48
- NVCT N/A
- Revenue
- RMAX $298,162,000.00
- NVCT N/A
- Revenue This Year
- RMAX N/A
- NVCT N/A
- Revenue Next Year
- RMAX N/A
- NVCT N/A
- P/E Ratio
- RMAX $20.66
- NVCT N/A
- Revenue Growth
- RMAX N/A
- NVCT N/A
- 52 Week Low
- RMAX $6.90
- NVCT $4.44
- 52 Week High
- RMAX $14.31
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- RMAX 63.07
- NVCT 42.49
- Support Level
- RMAX $9.64
- NVCT $6.15
- Resistance Level
- RMAX $9.92
- NVCT $6.61
- Average True Range (ATR)
- RMAX 0.31
- NVCT 0.27
- MACD
- RMAX 0.02
- NVCT 0.01
- Stochastic Oscillator
- RMAX 70.80
- NVCT 5.48
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.